| Mechanisms of adiponectin regulation and use as a pharmacological target. | |
| | |
MedLine Citation:
|
PMID: 20810317 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Adiponectin is an insulin-sensitizing and anti-inflammatory fat cell hormone that has immense potential as a therapeutic target for a multitude of obesity-associated diseases, including type 2 diabetes, NASH and atherosclerosis (Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone?Diabetes Care 2003, 26:2442-2450). The adiponectin gene is located in chromosome 3q27, a susceptibility locus for T2DM and metabolic disorders (Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu N, Tomita M: Organization of the gene for gelatin-binding protein (GBP28). Gene 1999, 229:67-73). Increased circulating levels of adiponectin are associated with improvement in the metabolic syndrome and reductions are strongly predictive of diabetes risk (Li S, Shin HJ, Ding EL, van Dam RM: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188. Extensive efforts have been made to understand how adiponectin levels can be elevated. The complex post-translational processing and secretion of adiponectin provides a rich area where pharmacologic manipulation may be developed to increase adiponectin levels in humans. Circulating adiponectin levels are increased by many commonly used drugs, such as statins, angiotensin converting enzyme (ACE) inhibitors, and thiazolidinediones (TZDs) providing an important opportunity to gain insight into the mechanisms underlying their effects. This review describes the cellular processes by which adiponectin is synthesized and secreted, current therapeutics known to affect this pathway and the potential for therapeutic manipulation in human subjects. |
| | |
Authors:
|
Susan A Phillips; Jacqueline T Kung |
Related Documents
:
|
19013287 - Regulation of adiponectin secretion by insulin and amino acids in 3t3-l1 adipocytes. 17506117 - Leptin in embryos from control and diabetic rats during organogenesis: a modulator of n... 19059527 - Relationships between plasma adiponectin and body fat distribution, insulin sensitivity... 10193827 - Peritoneal clearance of leptin in capd patients: impact of local insulin administration. 14755807 - Intracoronary brachytherapy, a promising treatment option for diabetic patients: result... 15758817 - Effect of basic fibroblast growth factor incorporating gelatin microspheres on erectile... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in pharmacology Volume: 10 ISSN: 1471-4973 ISO Abbreviation: Curr Opin Pharmacol Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100966133 Medline TA: Curr Opin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 676-83 Citation Subset: IM |
Copyright Information:
|
Published by Elsevier Ltd. |
Affiliation:
|
Medicine Service, Section of Endocrinology, Diabetes and Metabolism, Veterans Administration Medical Center San Diego, CA, USA. saphillips@ucsd.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluating the biological complexity of animal models of human disease and emerging therapeutic moda...
Next Document: The elusive identity of T follicular helper cells.